Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Nykode Therapeutics

    - PMLiVE

    AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

    Around one in five breast cancer cases are HER2-positive

    - PMLiVE

    Medicus Pharma completes patient enrolment for basal cell carcinoma trial

    Interim results have shown over 60% clinical clearance in patients treated with SkinJect

    - PMLiVE

    Researchers at University of Geneva develop test platform for cancer treatments

    The new platform could speed up testing while reducing the need for animal models

    - PMLiVE

    Regeneron’s Libtayo receives EC approval for skin cancer

    Phase 3 trial results showed the drug significantly improved disease-free survival

    Quote from the article: Without adapting JCA to include assessment of real-world data and broader benefits, vaccines may be undervalued

    Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?

    By Emily Morton-West

    Amiculum

    - PMLiVE

    Merck and Blackstone agree on funding for cancer protein antibody

    The funding will support late-stage clinical development of the investigational antibody-drug conjugate

    - PMLiVE

    Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

    The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

    - PMLiVE

    Eli Lilly’s Inluriyo approved by FDA for breast cancer

    The oral drug can be used to treat advanced or metastatic breast cancer

    - PMLiVE

    A Call to Action: Bridging the Adult Immunization Divide

    Over the past few years, as new diseases have emerged or reemerged, a host of new vaccines have become available while many others are in the pipeline. For older adults,...

    Medscape Education

    - PMLiVE

    Lilly and Circle Pharma agree to collaborate on new oral macrocycle therapies

    The agreement is part of the Lilly Catalyze360 model, designed to empower early-stage biotechs

    - PMLiVE

    What oncologists really want from booth strategy

    Simon Davenport, Global Head of Environments, Emota, an Inizio Engage company  At this year’s ASCO® congress, the spotlight wasn’t just on science – it was on how the industry engages. Supporting over 30...

    Inizio

    - PMLiVE

    How smart spaces and real-time strategy transformed ASCO® 2025

    Nick Bellomo, Director of Technology and Engagement, Inizio Medical ASCO® 2025 wasn’t just about oncology breakthroughs - it was also a showcase for how technology is redefining congress engagement. Supporting...

    Inizio

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links